Journey Strategic Wealth’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.62M Buy
57,557
+5,905
+11% +$157K 0.04% 128
2025
Q4
$1.29M Sell
51,652
-4,874
-9% -$123K 0.03% 139
2025
Q3
$1.44M Buy
56,526
+7,341
+15% +$181K 0.04% 124
2025
Q2
$1.19M Buy
49,185
+20,630
+72% +$481K 0.04% 137
2025
Q1
$724K Buy
28,555
+3,210
+13% +$84K 0.03% 172
2024
Q4
$672K Sell
25,345
-10,947
-30% -$297K 0.03% 174
2024
Q3
$1.05M Buy
36,292
+11,738
+48% +$342K 0.04% 122
2024
Q2
$687K Buy
24,554
+3,102
+14% +$85.4K 0.03% 131
2024
Q1
$595K Buy
21,452
+13,763
+179% +$382K 0.03% 117
2023
Q4
$221K Sell
7,689
-8,685
-53% -$263K 0.01% 184
2023
Q3
$543K Sell
16,374
-2,857
-15% -$101K 0.03% 78
2023
Q2
$705K Sell
19,231
-8,167
-30% -$318K 0.03% 73
2023
Q1
$1.12M Buy
27,398
+4,096
+18% +$177K 0.12% 54
2022
Q4
$1.19M Buy
23,302
+1,589
+7% +$76.2K 0.14% 51
2022
Q3
$951K Buy
21,713
+1,437
+7% +$69.8K 0.13% 45
2022
Q2
$1.06M Buy
20,276
+565
+3% +$28.8K 0.14% 36
2022
Q1
$1.02M Buy
19,711
+654
+3% +$33.9K 0.11% 28
2021
Q4
$1.13M Buy
+19,057
New +$944K 0.12% 39

Other funds holding PFE

Journey Strategic Wealth's PFE Position: Q1 2026 in Review

Journey Strategic Wealth increased its Pfizer (PFE) stake by 11% in Q1 2026, buying an estimated $157K and bringing the position to 57,557 shares worth $1.62M. The position accounts for 0.04% of the portfolio, ranked #128.

Journey Strategic Wealth first reported a position in PFE in Q4 2021 and has held it in 18 quarters since. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Journey Strategic Wealth held 57,557 shares of Pfizer worth $1.62M as of Q1 2026.
  • Journey Strategic Wealth bought 5,905 Pfizer shares in Q1 2026, an estimated $157K.
  • Pfizer made up 0.04% of Journey Strategic Wealth's portfolio in Q1 2026, its #128 holding.
  • Journey Strategic Wealth first reported a position in Pfizer in Q4 2021 and has held it in 18 quarters since.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Journey Strategic Wealth's 13F filing for Q1 2026, filed 15 Apr 2026.